Evidence map›Paper›PMID 36765522›Full record

ReviewCancers2023

Immunotherapy: Review of the Existing Evidence and Challenges in Breast Cancer.

Yun Hu, Yan Li, Zhangcheng Yao, Fenglin Huang, Hongzhou Cai, Hanyuan Liu, Xiaoyi Zhang, Junying Zhang

Abstract readReview
In one paragraph

Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yun HuDepartment of Breast Cancer, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210009, China.
Yan LiDepartment of Radiology, The Fourth School of Clinical Medicine, Nanjing Medical University, Nanjing 210029, China.
Zhangcheng YaoDepartment of Radiology, The Fourth School of Clinical Medicine, Nanjing Medical University, Nanjing 210029, China.
Fenglin HuangDepartment of Radiology, The Fourth School of Clinical Medicine, Nanjing Medical University, Nanjing 210029, China.
Hongzhou CaiDepartment of Radiology, The Fourth School of Clinical Medicine, Nanjing Medical University, Nanjing 210029, China.ORCID 0000-0001-6915-564X
Hanyuan LiuDepartment of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.
Xiaoyi ZhangDepartment of Radiology, The Fourth School of Clinical Medicine, Nanjing Medical University, Nanjing 210029, China.
Junying ZhangDepartment of Radiology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210009, China.

Funding

National Natural Science Foundation of China 82202890The Fund of Jiangsu Cancer Hospital 202013
6 · The paper itself

Abstract

Breast cancer (BC) is a representative malignant tumor that affects women across the world, and it is the main cause of cancer-related deaths in women. Although a large number of treatment methods have been developed for BC in recent years, the results are sometimes unsatisfying. In recent years, treatments of BC have been expanded with immunotherapy. In our article, we list some tumor markers related to immunotherapy for BC. Moreover, we introduce the existing relatively mature immunotherapy and the markers' pathogenesis are involved. The combination of immunotherapy and other therapies for BC are introduced in detail, including the combination of immunotherapy and chemotherapy, the combined use of immunosuppressants and chemotherapy drugs, immunotherapy and molecular targeted therapy. We summarize the clinical effects of these methods. In addition, this paper also makes a preliminary exploration of the combination of immunotherapy, radiotherapy, and nanotechnology for BC.

Indexed as

breast cancerimmunotherapymonoclonal antibodiesPD-1/PD-L1

Identifiers

PMID36765522
PMCPMC9913569

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.